VEGF	O
-	O
targeted	O
therapy	O
:	O
therapeutic	O
potential	O
and	O
recent	O
advances	O
.	O

After	O
over	O
30	O
years	O
of	O
theorizing	O
,	O
the	O
use	O
of	O
angiogenesis	O
inhibitors	O
as	O
anticancer	B-Cancer
therapy	O
has	O
finally	O
moved	O
from	O
the	O
realm	O
of	O
research	O
to	O
reality	O
.	O

Normal	O
adult	O
vasculature	B-Anatomical_system
is	O
generally	O
quiescent	O
in	O
nature	O
,	O
with	O
endothelial	B-Cell
cells	I-Cell
dividing	O
approximately	O
every	O
10	O
years	O
.	O

In	O
contrast	O
,	O
the	O
growth	O
of	O
tumors	B-Cancer
requires	O
constant	O
vascular	B-Multi-tissue_structure
growth	O
and	O
remodeling	O
in	O
order	O
for	O
solid	B-Cancer
tumors	I-Cancer
to	O
grow	O
beyond	O
1	O
-	O
2	O
mm	O
(	O
3	O
)	O
in	O
size	O
.	O

Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
and	O
its	O
receptors	O
are	O
key	O
regulators	O
of	O
the	O
process	O
of	O
angiogenesis	O
,	O
which	O
makes	O
them	O
attractive	O
therapeutic	O
targets	O
.	O

A	O
multitude	O
of	O
VEGF	O
-	O
targeted	O
inhibitory	O
agents	O
are	O
currently	O
being	O
investigated	O
for	O
the	O
treatment	O
of	O
cancer	B-Cancer
.	O

This	O
review	O
article	O
focuses	O
on	O
recent	O
developments	O
in	O
the	O
use	O
of	O
angiogenesis	O
inhibitors	O
for	O
the	O
treatment	O
of	O
breast	B-Cancer
,	O
lung	B-Cancer
,	O
and	O
colorectal	B-Cancer
cancers	I-Cancer
.	O

